ResMed Inc. (NYSE:RMD) CFO Brett Sandercock sold 1,250 shares of ResMed stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $84.99, for a total value of $106,237.50. Following the transaction, the chief financial officer now owns 78,322 shares in the company, valued at approximately $6,656,586.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Brett Sandercock also recently made the following trade(s):

  • On Friday, December 1st, Brett Sandercock sold 1,250 shares of ResMed stock. The stock was sold at an average price of $85.36, for a total value of $106,700.00.
  • On Wednesday, November 1st, Brett Sandercock sold 1,250 shares of ResMed stock. The stock was sold at an average price of $84.50, for a total value of $105,625.00.

ResMed Inc. (NYSE:RMD) traded up $0.89 during trading on Thursday, hitting $86.42. The stock had a trading volume of 481,300 shares, compared to its average volume of 404,850. ResMed Inc. has a fifty-two week low of $61.63 and a fifty-two week high of $87.81. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.72 and a quick ratio of 3.86. The stock has a market cap of $12,137.04, a P/E ratio of 34.99, a P/E/G ratio of 1.88 and a beta of 0.79.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.66. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The business had revenue of $523.66 million during the quarter, compared to the consensus estimate of $506.08 million. During the same period in the previous year, the business earned $0.62 EPS. The business’s quarterly revenue was up 12.5% on a year-over-year basis. sell-side analysts forecast that ResMed Inc. will post 3.03 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Thursday, December 14th. Investors of record on Thursday, November 9th were given a $0.35 dividend. This represents a $1.40 annualized dividend and a yield of 1.62%. The ex-dividend date was Wednesday, November 8th. ResMed’s dividend payout ratio (DPR) is presently 56.68%.

A number of hedge funds have recently modified their holdings of RMD. Cubist Systematic Strategies LLC acquired a new position in ResMed during the 3rd quarter worth approximately $113,000. YorkBridge Wealth Partners LLC increased its position in ResMed by 4.9% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock worth $115,000 after purchasing an additional 69 shares during the period. Toronto Dominion Bank increased its position in ResMed by 12.8% during the 2nd quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock worth $135,000 after purchasing an additional 197 shares during the period. BB&T Investment Services Inc. acquired a new position in ResMed during the 2nd quarter worth approximately $214,000. Finally, Visionary Asset Management Inc. acquired a new position in ResMed during the 3rd quarter worth approximately $214,000. Hedge funds and other institutional investors own 61.85% of the company’s stock.

Several research firms have issued reports on RMD. BMO Capital Markets raised their target price on ResMed to $82.00 and gave the stock a “market perform” rating in a research note on Tuesday, December 12th. Zacks Investment Research cut ResMed from a “hold” rating to a “sell” rating in a research note on Tuesday, December 26th. JPMorgan Chase & Co. boosted their target price on ResMed from $72.00 to $73.00 and gave the stock an “overweight” rating in a research note on Monday, October 30th. Needham & Company LLC reissued a “sell” rating on shares of ResMed in a research note on Friday, September 8th. Finally, Barclays lifted their price target on ResMed from $68.00 to $70.00 and gave the stock an “underweight” rating in a report on Friday, October 27th. Five equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $68.71.

WARNING: “ResMed Inc. (RMD) CFO Sells $106,237.50 in Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/04/resmed-inc-rmd-cfo-sells-106237-50-in-stock.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.